Protective drug for D-GaIN/LPS induced liver injury

Abstract

The invention belongs to the technical field of medicine and pharmacology and discloses a protective drug for D-GaIN/LPS induced liver injury. The protective drug for induced liver injury is daucosterol. It is indicated herein that daucosterol has anti-inflammatory and immunoregulatory activities; daucosterol may promote generation of CD4+T cells to assist a mouse to resist disseminated candidiasis when used to treat the mouse with disseminated candidiasis; a mouse model with galactosamine lipoxygenase induced liver injury is commonly used to analyze pyemic liver injury; daucosterol is used herein to intervene the mouse model with D-GaIN/LPS induced liver injury, the protective action and possible mechanism of daucosterol against D-GaIN/LPS induced liver injury is explored, and daucosterolis significant to analyze a drug to treat pyemia.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a medicine for protecting liver damage induced by D-GaIN / LPS. Background technique [0002] At present, the existing technologies commonly used in the industry are as follows: [0003] Sepsis is a destructive systemic inflammatory response caused by infection (bacteria, virus, fungus, etc.), which leads to disorders of the body's immune system, coagulation / fibrinolytic system, metabolism, and microcirculation, and can eventually induce multiple organ dysfunction and injury. Clinical syndromes of septic shock. Sepsis is one of the most common critical illnesses in the ICU and has become the third leading cause of death in patients with high morbidity and high mortality. There are an average of more than 18 million cases of severe sepsis every year in the world. In the United States, there are about 700,000 sepsis patients every year, and more than 200,000 patients d...

AI Technical Summary

Problems solved by technology

[0009] (1) Clinically commonly used therapeutic drugs such as broad-spectrum antibacterial drugs, glucocorticoids, immunoglobulins, insulin, and coagulation-regulating drugs have large individual differences in drug use, and the side effects of drugs are obvious, so the patient's tolerance and compliance are not good

In addition, the prices of immunoglobulin, insulin, and coagulation-regulating drugs are relatively high, which brings a large economic burden to patients

[0010] (2) Other adjuvant treatment methods such as the type of resuscitation fluid and resuscitation volume are still controversial and have not yet been quantified; blood purification or the effect is not as expected or the side effects are obvious, and the medical cost is relatively high; Professional technicians operate, and cannot be carried out in grassroots and economically backward areas

[0011] (3) The traditional Chinese medicine treatment of sepsis is mostly based on prescriptions and unit medicines, limited by the constraints of traditional Chinese medicine extraction technology, there are few reports on the analysis of monomer compounds, and only preliminary evidence of anti-inflammatory or immune-regulating effects of drugs, and The mechanism has not been further explored

[0013] There are many difficulties in solving the above problems. It is difficult to optimize the efficacy of drugs and reduce adverse drug reactions. The limitations of analysis and development cause safety problems after large-scale use of drugs; non-standard clinical use causes problems in the effectiveness and safety of preparations; The research and development costs of surgical operations such as blood purification are relatively high, there are many technical problems to be solved, and the operation requires the support of professional technicians

Solving the above problems requires huge financial support, which in turn increases the cost of treatment and aggravates the economic burden on patients and society

Images